INCY 20 Pill - white capsule/oblong, 16mm
Generic Name: ruxolitinib
Pill with imprint INCY 20 is White, Capsule/Oblong and has been identified as Jakafi 20 mg. It is supplied by Incyte Corporation.
Jakafi is used in the treatment of Myelofibrosis; Polycythemia Vera; Graft-versus-host disease; Myeloproliferative Disorders and belongs to the drug class multikinase inhibitors. Risk cannot be ruled out during pregnancy. Jakafi 20 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for INCY 20
Jakafi
- Generic Name
- ruxolitinib
- Imprint
- INCY 20
- Strength
- 20 mg
- Color
- White
- Size
- 16.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Incyte Corporation
- National Drug Code (NDC)
- 50881-0020
- Inactive Ingredients
-
microcrystalline cellulose,
lactose monohydrate,
silicon dioxide,
hydroxypropyl cellulose (type e),
povidone,
sodium starch glycolate type A potato,
magnesium stearate
Note: Inactive ingredients may vary.
More about Jakafi (ruxolitinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (32)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
